Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Overview of attention for article published in Journal for Immunotherapy of Cancer, January 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#47 of 3,485)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 12 news stories from 12 outlets.

SYDNEY, Australia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a…

SYDNEY, Australia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Immutep (Formerly known as Prima Biomed) (ASX: IMM; NASDAQ: IMMP) ("Immutep…

I hope that this newsletter finds you and your families safe and well. Australia, Aug.

SYDNEY, Australia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP)Â ("Immutepâ€? or â€œthe Companyâ€?…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 8 additional news stories.